Nektar to Hold Conference Call to Discuss Topline Results From the 36-Week Maintenance Period for Its Rezolve-Ad Phase 2B Study of Rezpegaldesleukin in Atopic Dermatitis on February 10, 2026
Nektar to Hold Conference Call to Discuss Topline Results From the 36-Week Maintenance Period for Its Rezolve-Ad Phase 2B Study of Rezpegaldesleukin in Atopic Dermatitis on February 10, 2026
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.